Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Report Date: May 13, 2026
Principal Executive Office: Marseille, France
This filing incorporates by reference a press release (Exhibit 99.1) dated May 13, 2026, into the company's registration statements on Form F-3 and Form S-8. The document serves as a formal notification of the press release content to the SEC.
Key Financial Metrics
The provided filing text does not contain specific financial data. It is a cover document referencing an external press release. Consequently, the following metrics are not available in this text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Material Changes
The filing text does not provide details on material changes versus prior periods. The specific nature of the update is contained within the referenced Exhibit 99.1 (Press Release), which is not included in the input text.
Guidance, Outlook, and Risks
Management Commentary: The filing references a quotation from Jonathan Dickinson, Chief Executive Officer, within the incorporated press release, but the text of the quotation is explicitly excluded from this Form 6-K document.
Outlook and Risks: No specific guidance, outlook, risks, contingencies, or unusual items are detailed in the provided text.
Investor Verification Checklist
- Review the full text of the Press Release dated May 13, 2026 (Exhibit 99.1) to understand the specific corporate event or announcement.
- Verify the content of the CEO's quotation, which was excluded from this filing summary.
- Check the referenced registration statements (Form F-3 File No. 333-276164 and Form S-8 File No. 333-282031) for updated prospectuses incorporating this news.
- Confirm if the press release contains material financial updates or clinical trial results not present in this cover letter.